Biotechnology, Gene-editing and Medical Research Stocks to Buy in 2019

(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative.

There is nothing more powerful than a base breakout, and this had one in February of this year. This one is on a trend line right now and there is absolutely nothing wrong with the chart.

Very positive on the stock price, the company, and the partnerships they're announcing. Technicals indicate the stock may head toward 90 cents, but he says higher. Just won a contract from the Ontario government. Covid testing isn't going away. Sales should triple in the next 12 months.

Real-time, remote medical reporting from patient to care providers. Fits and starts over the years. Should be rolling up to cashflow positive. Nice runway with great growth rate. Adding new partners. Monthly subscription. Could have a bright future in next couple of years.

Doesn't know this well. They're in the cannabis sector, more in the extraction market, an area that will continue to expand. He's watching their progress in earnings.

Their gene-editing biotechnology has lots of promise, but it's too early to tell, speculative. Buying this is a lottery ticket.

Large cap biotech. Its two franchises are dominant: macular degeneration and atopic dermatitis. One of the best at R&D. Proven ability to execute. One of the better growth profiles for next 3-5 years. Bit of volatility around reimbursement. Decent valuation. No dividend.

(A Top Pick May 8/17. Up 11.02%.) The period of seasonal strength for this is usually early May right through until the middle of July. We have reached the point where seasonality no longer applies. Now is a good time to take the money off the table.

(A Top Pick Oct 27/20, Up 6.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with GILD has triggered its stop at $64. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.

The entire drug sector hasn't been investable since the 1990s, because governments control drug prices and patent expiries. Pfizer is struggling to replace drugs coming off patent, like their cholesterol drug. It's really tough. It's a defensive sector, so the drug companies will hold up better and offer dividend growth.

They own almost nothing in the Health Care space and Biotech is particularly weak.

(A Top Pick Dec 29/21, Up 21.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMY is progressing well. To remain disciplined, we recommend trailing up the stop (from $68) to $72.

Made big money by selling off one division. Decent pipelines. Looking to sell off generic division. Dividend grows, share buybacks. Healthcare has become front and centre, and that's not going away. Safe haven. Underpriced at these levels. Yield is 3.55%. (Analysts’ price target is $88.96)

(A Top Pick Nov 03/20, Up 17.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN is progressing well. We now recommend trailing up the stop (from $218) to $228.

TEVA-N vs. MYL-Q. He does not like either at these prices. They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals. The FDA is going to alleviate the delays on getting new drugs to market. He wants to be…

LLY vs. NVO NVO is focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd…

(A Top Pick Jan 15/21, Down 7%) Company has increased dividend for almost 50 years, however needs a good acquisition to grow. Stock price is low which creates a buying opportunity. Will continue to buy and hold.

Top healthcare pick. Valuation is rich, though the dividend is decent. He will suggest a better stock in Top Picks.

Their last quarter was very good, beating the street, but shares have been down. Part of their growth came from Covid testing, which grew well. Their medical devices business was up 8%, though the last two years halted elective surgeries. This hurt ABT but will improve (like JNJ did) because there's a huge backlog of…

The company supplies hospitals with medical supplies. 90% of their products are disposable. They have been hurt from COVID as operations have been delayed and it looks that may continue. In a normalized time, they are well situated for an aging population, which should translate into double-digits earnings growth going forward.

They make medical devices. They bought a medical company focused on hands. Again demographics will increase demand for knee and hip replacements. Also, doctors seldom change device-makers, so they will stick with Stryker. They have little presence outside the U.S. so there are opportunities for growth there. Also, there's a backlog in elective surgeries.

This is funny in terms of a long-term outlook. They have a buildings supplies business, and the hospital protection business. Whenever there is a pandemic in the works, this company takes off. It has been moving around $4 per share, and thinks it could go a fair bit higher. He would like to get $6+…